Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitaplatin vs epirubicin TACE in hepatocellular carcinoma
CTR20171501Phase 3Terminated
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitaplatin in hepatocellular carcinoma (HCC), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Started Dec 2017; status: terminated.
02
Drugs
mitaplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20171501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171501.